NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: DRREDDY · data 2026-10-31
Dr. Reddy's Laboratories Ltd.
In plain words
Price: 4.4% below its 52-week high of ₹1,414.9.
Delivery: 51.6% of traded shares were kept for delivery over the last 10 sessions, against 55.8% over the last 60.
Latest results: a net profit of ₹925 cr for the quarter ended Sept 2026 (-31.3% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹32,984 cr |
| Net profit (last 12 months) | ₹2,798 cr |
| Sales growth, 3 years (yearly) | 11.0% |
| Profit growth, 3 years (yearly) | -1.7% |
At a glance
Promoters 26.6% (unchanged in a year), pledged 0.0%, institutions 63.3%.
P/E 40.3, P/B 2.9, dividend yield 0.6%. Price relative to earnings and book value (low is cheaper, not better).
ROE 12.1%, ROCE 12.1%, operating margin 8.9%: how much profit it earns on the money it uses.
Debt/equity 0.21, Profit growth -1.7% and sales growth 11.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
None flagged by these rules.
- Profit fell 1.7% a year over 3 years.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
DRREDDY Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹8,697.8 crore, down 1.5% YoY and up 7.4% QoQ.
Net profit was ₹924.8 crore, down 31.3% YoY and up 108.1% QoQ.
Operating margin was 19.9% (22.8% a year ago).
EPS was ₹11.1, down 31.4% YoY and up 108.3% QoQ.
DRREDDY के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹8,697.8 करोड़; पिछले साल की तुलना में 1.5% की गिरावट, पिछली तिमाही की तुलना में 7.4% की बढ़त।
शुद्ध मुनाफ़ा: ₹924.8 करोड़; पिछले साल की तुलना में 31.3% की गिरावट, पिछली तिमाही की तुलना में 108.1% की बढ़त।
ऑपरेटिंग मार्जिन: 19.9% (एक साल पहले 22.8%)।
EPS: ₹11.1; पिछले साल की तुलना में 31.4% की गिरावट, पिछली तिमाही की तुलना में 108.3% की बढ़त।
DRREDDYના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹8,697.8 કરોડ; ગયા વર્ષની સરખામણીએ 1.5% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 7.4% વધારો.
ચોખ્ખો નફો: ₹924.8 કરોડ; ગયા વર્ષની સરખામણીએ 31.3% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 108.1% વધારો.
ઓપરેટિંગ માર્જિન: 19.9% (એક વર્ષ પહેલાં 22.8%).
EPS: ₹11.1; ગયા વર્ષની સરખામણીએ 31.4% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 108.3% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
40/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 3/30: Delivery 50.0% over the last 20 sessions vs 56.7% in the 40 before (0.88x); shares delivered per day 1.18x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 6/15: 0 insider buy days (promoter group among them) and 1 SAST acquisition day in 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 45 schemes hold it, about ₹5,728 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 13/15: Verdict "Sustained", sustained score 62/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Insider ● Results ● Dividend
- 18 Aug 26Insider SAST disclosure: ICICI Prudential Mutual Fund acquired 7,12,884 shares -1.8% next session
- 22 Jul 26Results Q1 FY27 results: profit −68.7% YoY -3.3% next session
- 10 Jul 26Dividend Dividend ₹8 (ex-date) -2.8% next session
- 12 May 26Results Q4 FY26 results: profit −86.1% YoY -1.1% next session
- 21 Jan 26Results Q3 FY26 results: profit −14.4% YoY +4.4% next session
- 24 Oct 25Results Q2 FY26 results: profit +7.3% YoY +0.4% next session
- 23 Jul 25Results Q1 FY26 results: profit +1.8% YoY +2.1% next session
- 10 Jul 25Dividend Dividend ₹8 (ex-date) -1.2% next session
- 9 May 25Results Q4 FY25 results: profit +21.6% YoY +4.1% next session
- 24 Jan 25Results Q3 FY25 results: profit +2.4% YoY -7.1% next session
- 5 Nov 24Results Q2 FY25 results: profit −15.3% YoY +2.7% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹8,698 cr | ₹925 cr | -31.3% | 19.9% | 11.1 |
| Jun 2026 | ₹8,100 cr | ₹444 cr | -68.7% | 10.6% | 5.33 |
| Mar 2026 | ₹7,546 cr | ₹221 cr | -86.1% | 5.1% | 2.65 |
| Dec 2025 | ₹8,753 cr | ₹1,210 cr | -14.4% | 21.6% | 14.53 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 26.63% | 26.64% | 26.63% | 26.64% |
| Foreign institutions (FII) | 31.39% | 32.07% | 33.08% | 33.20% |
| Domestic institutions (DII) | 31.88% | 31.74% | 30.72% | 30.44% |
| Mutual funds | 14.14% | 13.16% | 13.19% | 13.87% |
| Retail investors | 7.45% | 7.34% | 7.46% | 7.64% |
| Number of shareholders | 4,76,681 | 4,46,086 | 4,49,665 | 4,55,243 |
Common questions
What was Dr. Reddy's Laboratories Ltd.'s latest quarterly profit?
Dr. Reddy's Laboratories Ltd. reported a net profit of ₹925 cr for the quarter ended Sept 2026 (-31.3% on the same quarter a year earlier), on revenue of ₹8,698 cr.
How much do promoters hold in Dr. Reddy's Laboratories Ltd.?
Promoters held 26.63% of Dr. Reddy's Laboratories Ltd. at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Dr. Reddy's Laboratories Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.21.
What is Dr. Reddy's Laboratories Ltd.'s P/E ratio?
About 40.3, based on the last 12 months' earnings and a price of ₹1,352 (data 2026-10-31).
What is the 52-week high and low of Dr. Reddy's Laboratories Ltd.?
The 52-week high is ₹1,414.9 and the 52-week low is ₹1,101.
Mutual funds holding Dr. Reddy's Laboratories Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 45 schemes holding about ₹5,728 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Parag Parikh Flexi Cap Fund | PPFAS Mutual Fund | 1.23% | ₹1,784 cr |
| SBI Nifty 50 ETF | SBI Mutual Fund | 0.72% | ₹1,462 cr |
| NIPPON INDIA PHARMA FUND | Nippon India Mutual Fund | 5.45% | ₹500 cr |
| NIPPON INDIA LARGE CAP FUND | Nippon India Mutual Fund | 0.96% | ₹492 cr |
| NIPPON INDIA ETF NIFTY 50 BEES | Nippon India Mutual Fund | 0.72% | ₹469 cr |
| Mirae Asset Large Cap Fund | Mirae Asset Mutual Fund | 0.62% | ₹221 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 4.84% | ₹169 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 7.62% | ₹132 cr |
| SBI Nifty Index Fund | SBI Mutual Fund | 0.72% | ₹95 cr |
| Parag Parikh ELSS Tax Saver Fund | PPFAS Mutual Fund | 1.39% | ₹75 cr |
| Nippon India Flexi Cap Fund | Nippon India Mutual Fund | 0.74% | ₹68 cr |
| Mirae Asset Aggressive Hybrid Fund | Mirae Asset Mutual Fund | 0.63% | ₹58 cr |
| Mirae Asset Nifty 50 ETF | Mirae Asset Mutual Fund | 0.72% | ₹38 cr |
| NIPPON INDIA INDEX FUND - NIFTY 50 PLAN | Nippon India Mutual Fund | 0.72% | ₹25 cr |
| ADITYA BIRLA SUN LIFE NIFTY 50 ETF | Aditya Birla Sun Life Mutual Fund | 0.72% | ₹23 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Dr. Reddy's Laboratories Ltd. | ₹1,352 | ₹1,12,643 cr | 40.3 | 2.9 | 12.1% | 12.1% | 0.21 | +13.0% |
| Torrent Pharmaceuticals Ltd | ₹4,613.4 | ₹1,76,300 cr | 75.6 | 9.6 | 27.1% | 13.5% | 1.79 | +28.0% |
| Laurus Labs Ltd. | ₹2,405.5 | ₹1,29,243 cr | 97.1 | 21.5 | 18.2% | 20.5% | 0.48 | +149.8% |
| Zydus Lifesciences Limited | ₹1,245.5 | ₹1,24,089 cr | 27.8 | — | 19.7% | 17.8% | 0.46 | +24.1% |
| Mankind Pharma Ltd. | ₹2,492.8 | ₹1,02,797 cr | 46 | 5.9 | 12.5% | 12.7% | 0.39 | +1.4% |
| Glenmark Pharmaceuticals Limited | ₹2,298.7 | ₹65,137 cr | 36.1 | — | 14.1% | 29.2% | 0.06 | +24.1% |
Compare DRREDDY with TORNTPHARM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open DRREDDY in NSE Scanner →